Related Experiment Videos
Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period
N De Maria1, A Colantoni, E Rosenbloom
1Gastroenterology and Nutrition, Department of Medicine, University of Kentucky, Lexington, USA.
Insights
Ursodeoxycholic acid and colchicine were found to be ineffective for treating primary sclerosing cholangitis. This study showed no significant difference in liver health outcomes between treated and untreated patients over two years.
Area of Science:
- Hepatology
- Gastroenterology
- Clinical Trials
Background:
- Ursodeoxycholic acid (UDCA) is used for primary biliary cirrhosis and autoimmune hepatitis.
- Its proposed mechanisms include detergent action, choleresis, reduced HLA expression, and impaired T cell reactivity.
- Primary sclerosing cholangitis (PSC) is a chronic liver disease with limited treatment options.
Purpose of the Study:
- To evaluate the efficacy of ursodeoxycholic acid (UDCA) in treating primary sclerosing cholangitis (PSC).
- To compare UDCA with colchicine and a control group in PSC patients.
Main Methods:
- A 24-month randomized controlled study involving 59 PSC patients.
- Three groups: UDCA (300 mg BID), colchicine (0.6 mg BID), and untreated control.
- Regular 3-month follow-ups with quarterly, annual, and terminal assessments.
Main Results:
- No significant differences in liver injury, function, size, or copper content after two years.
- Endoscopic retrograde cholangiopancreatography (ERCP) findings remained similar across all groups.
- No therapeutic benefit observed for UDCA or colchicine compared to the control.
Conclusions:
- Ursodeoxycholic acid (UDCA) demonstrated no superiority over colchicine or standard medical care for PSC.
- Neither UDCA nor colchicine are effective therapies for primary sclerosing cholangitis (PSC).
- Further research into effective PSC treatments is warranted.
Background:
Ursodeoxycholic acid has been shown to be a useful agent in the clinical management of patients with primary biliary cirrhosis and autoimmune chronic active hepatitis. Its efficacy is presumed to be based upon its ability to act as a detergent and to incite a choleresis. Recent additional data suggest it also reduces HLA antigen expression on liver and biliary epithelial cells and impairs T cell reactivity.
Methods:
A randomized controlled study of 59 patients with primary sclerosing cholangitis was performed over a 24 months period with 3 groups being studied. Group I consisted of 20 patients who were given ursodeoxycholic acid 300 mg orally twice a day; group II consisted of 19 patients who were given colchicine 0.6 mg orally BID; and group III was an untreated medical control group. All three groups were seen at regular 3-month intervals and had quarterly, annual and terminal studies performed to assess their disease status.
Results:
No difference between groups was evident after two full years of therapy when parameters of liver injury, liver function, liver size and hepatic copper content were compared between groups. Similarly, no difference in ERCP findings was evident between groups either at entry or after two years of therapy.
Conclusions:
These data suggest that ursodeoxycholic acid is no better than colchicine or simple medical follow-up. Thus, neither ursodeoxycholic acid or colchicine can be considered to be effective therapies for primary sclerosing cholangitis.